期刊文献+

环孢素A壳聚糖纳米粒修饰人工晶状体表面的实验研究 被引量:2

Experimental study on surface modification of intraocular lens by cyclosporine A-loaded chitosan nanoparticle
下载PDF
导出
摘要 背景 白内障囊外摘出术后发生后囊膜混浊(PCO)是影响患者术后视力的主要原因,目前探讨药物的局部应用来预防PCO已成为研究的热点. 目的 采用离子交联法制备环孢素A壳聚糖纳米粒(CyA-CS-NP),观察其体外释放性能及修饰聚甲基丙烯酸甲酯(PMMA)人工晶状体(IOL)边缘的可行性.方法 制备壳聚糖纳米粒(CS-NP)和CyA-CS-NP,用透射电子显微镜观察纳米粒的形态学特征,用高效液相色谱仪(HPLC)观察纳米粒的形态学特征、载药率、包载率及体外释药性能,并测定CyA-CS-NP修饰后IOL表面CyA的含量.CyA-CS-NP修饰经等离子处理PMMA IOL边缘,并用扫描电子显微镜观察IOL的表面特征.用X射线光电子能谱仪(XPS)检测单纯等离子体处理过的IOL和CyA-CS-NP修饰过的IOL边缘,分析并比较两种修饰方法处理的IOL表面的元素组成及化学键类型改变;用后焦距法和分光光度计分别测定IOL的屈光度和波长360~ 490 nm内的透光率,并参照ISO/CD 11979-2进行有效分辨率测试,检测IOL的光学性能;参照国际标准ISO/CD 11979-3测定IOL襻抗疲劳度测试. 结果 CS-NP和CyA-CS-NP呈单分散性、形状规则的类球形,粒径分别为(158±18)nm和(219±29) nm.CyA-CS-NP的平均包载率为64.2%,平均载药率为7.6%.体外缓释实验表明,第1天的快速释放阶段释药量达46.6%,此后为缓释阶段,在第12天时释药量达到77.7%.修饰后的IOL边缘存在CyA-CS-NP涂层,XPS检测显示IOL边缘存在CyA-CS-NP的特定元素及官能团,而等离子体处理的IOL未出现类似元素及官能团.3枚IOL表面负载CyA的平均质量为171.88 μg,修饰后的IOL屈光度、分辨率和透光率分别为(16.64±0.23)D、(90.28±0.25)%及(73.57±0.62)%,与修饰前的(16.62±0.29)D、(90.28±0.21)%及(73.61±0.60)%相比差异均无统计学意义(t=0.381、0.078、2.291,均P>0.05).IOL襻符合国际标准. 结论 与修饰前相比,经CyA-CS-NP边缘修饰的IOL光学性能和襻抗疲劳强度均无明显变化,符合国际标准,满足IOL的临床使用要求,可能成为眼内缓释给药的理想途径. Background Posterior capsular opacification (PCO) following cataract extracapsular extraction is a major cause of the reduction of visual acuity.Topical administration of eye drops is a research hotspot for the prevention of PCO.Objective This study was to evaluate the release of cyclosporine A-loaded chitosan nanoparticles (CyA-CS-NP) by ionic gelation in vitro and its feasibility of modification of the surface of polymethylmethacrylate intraocular lens (PMMA IOL) with CyA-CS-NP.Methods The CS-NP and CyA-CS-NP were prepared by ionic gelation of CS with sodium tripolyphosphate.The characteristics of CS-NP,such as the appearance and mean size,and drug entrapment efficient (EE),loading capacity (LC),and the drug release were studied ; the CyA content on the IOL surface was detected by high performance liquid chromatography (HPLC).The IOL surface modified with CyA-CS-NP was observed by scanning electron microscope and X-ray photoelectron spectroscopy technique (XPS),the changes of elements and chemical bond types between simple plasma processed IOL and CyA-CS-NP modified IOL were analyzed.The transmittance at the wavelength of 360-490 nm and refraction of IOL were detected using back focal length method and spectrophotometer,and the effective resolution of IOL was evaluated according to the instruction of ISO/CD 11979-2.Loops anti fatigue test of IOL referred to the criteria of ISO/CD 11979-3.Results The CS-NP and CyA-CS-NP showed monodisperse,uniform appearance similar to spherical shape with a mean size of (158±18) nm and (219±29) nm,respectively.The CyA-CS-NP had high CyA association efficiency and loading capacity (64.2% and 7.6%).In vitro release study revealed a fast release on the first day followed by a increased drug release during an 11-day following up.The sustained release was approximately 46.6% at day 1 and 77.7% at day 12,respectively.The surface of IOLs with cling film was smooth without CS-NP;while the edge of IOLs appeared a layer of CyA-CS-NP after modification.XPS analysis displayed some elements such as phosphonium,CNH2 and O =CN that appeared on the modified surface,indicating that CyA-CS-NP existed on the surface of IOLs edge.The mean quality of CyA on three IOLs surface after modification was 171.88 μg.The diopter,distinguishing ability and transmittance of modified IOL were (16.64±0.23) D,(90.28 ± 0.25) % and (73.57 ±0.62) %,and those of unmodified IOL were (16.62±0.29) D,(90.28±0.21) %,(73.61±0.60)%,without significant differences between them (t =0.381,0.078,2.291,all at P 〉 0.05).The antifatigue ability of loops complied with the criteria of ISO/CD 11979-3.Conclusions The optical property and antifatigue ability of loops of the edge-modified IOLs by CyA-CS-NP reach the normal standard and meet the requirement of clinic application.The edge-modified IOLs by CyA-CS-NP can be a delivery system for intraocular drug release.
出处 《中华实验眼科杂志》 CAS CSCD 北大核心 2013年第10期935-939,共5页 Chinese Journal Of Experimental Ophthalmology
关键词 壳聚糖纳米粒 环孢素A 人工晶状体 离子交联法 表面修饰 Chitosan nanoparticle Cyclosporin A Intraocular lens Ionic gelation Surface modification
  • 相关文献

参考文献2

二级参考文献12

  • 1David Williams. Medical nanotechnology: How small can we go[J]. Medical Device Technology,2002, 13(1) : 1-3.
  • 2James A, Ritter, Armin D, et al. Application of high gradient magnetic separation principles to magnetic drug targeting[J]. Journal of Magnetism and Magnetic Materials, 2004, 280 (2) : 184-201.
  • 3Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogarnicin in relapsed acute myeloid leukemia[J]. Clin Cancer Res, 2001, 7(6):1 490-1 496.
  • 4Morin C, Barratt G, Fessi H, et al. Improved interacellular delivery of a murarnyl dipeptide analog by means of nanocapsules [J]. Int J Immunpharmacol, 1994, 169(6):451-456.
  • 5Allemann E, Brasseur N, Benrezzak O, et al. PEG-coated poly (lactic acid ) nanoparticles for the delivery of hexadecafluoro zincphthalocyanine to EMT-T mouse mammary tumors [J]. J Pharm Pharmacol, 1995, 47(5) : 382-387.
  • 6Widder KJ, Senyei AE, Scrapeui DG, et al. Magnetic microsphere:A model system for site specific drug delivery in vivo[J].Pre Soc Expbiol Med, 1978, 158(1 ): 141-146.
  • 7R Iergta, R Hiergeista, I Hilgerb,et al. Maghemite nanoparticles with very high AC-losses for application in RF-magnetic hyperthermia[J]. Journal of Magnetism and Magnetic Materials, 2004, 270 (4) : 345-357.
  • 8Alexiou C, Arnold W, Klein RJ, et al. Loeoregional cancer treatment with magnetic drug targeting[J]. Cancer Res,2000,60(23), 6 641-6 648.
  • 9Lubbe AS,Bergemannc C, Riess H, et al. Precliical experiences with magnetic drug targeting a phase Ⅰ studd with 4 '-epidoxorubitin in 14 patients with advanced solid tumors[J]. Cancer Res, 1996,56(20) : 4 683-4 693.
  • 10Koping-Hoggard M, Mel'nikova YS, Varum KM, et al. Relationship between the physical shape and the efficiency of oligomeric ehitosan as a gene delivery system in vitro and in vivo[J].J Gene Med,2003, 5(2): 130-141.

共引文献17

同被引文献36

  • 1董晓光,徐玉梅,原公强,史伟云,谢立信,王身国.环孢素A缓释系统眼内植入治疗葡萄膜炎的实验研究[J].中华眼科杂志,2005,41(7):636-641. 被引量:10
  • 2兰小川,陈辉,顾海鹰,徐学东.环孢素A壳聚糖纳米微粒防治增生性玻璃体视网膜病变[J].眼科研究,2007,25(12):946-949. 被引量:4
  • 3Shimizu K, Kobayakawa S, Tsuji A, et al. Biofilm formation on hydrophilic intraocular lens material. Curr Eye Res, 2006, 31 (12): 989-997.
  • 4Matsushima I-I, Mukai K, Gotoo N, et al. The effects of drug de- livery via hydrophilic acrylic (hydrogel) intraocular lens systems on the epithelial cells in culture. Ophthalmic Surg Lasers Imaging, 2005, 36(5) : 386-392.
  • 5Weiner AL, Gilger BC. Advancements in ocular drug delivery. Vet Ophthalmol, 2010, 13(6) : 395-406.
  • 6Kleinmann G, Apple DJ, Chew J, et al. Hydrophilic acrylic in- traocular lens as a drug-delivery system for fourth-generation fluo- roquinolones. J Cataract Refract Surg, 2006, 32 (10) : 1717- 1721.
  • 7Lipnitzki I, Bronshtein R, Ben Eliahu S, et al. Hydrophilic acryl- ic intraocular lens as a drug delivery system : influence of the pre- soaking time and comparison to intracameral injection. J Ocul Pharmacol Ther, 2013, 29(4) : 414-418.
  • 8Wenk E, Meinel A J, Wildy S, et al. Microporous silk fibroin scaffolds embedding PLGA microparticles for controlled growth fac- tor delivery in tissue engineering. Biomaterials, 2009, 30 ( 13 ) .. 2571-2581.
  • 9Wenk E, Wandrey AJ, Merkle HP, et al. Silk fibroin spheres as a platform for controlled drug delivery. J Control Release, 2008, 132(1) : 26-34.
  • 10Gentile P, Chiono V, Carmagnola I, et al. An overview of poly (lactic-co-glycolic) acid (PLGA) -based biomaterials for bone tis- sue engineering. Int J Mol Sci, 2014, 15(3) : 3640-3659.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部